MedTrace Logo

Survey on Long-Term Use of BI-Sifrol® Tablets in Patients With Restless Legs Syndrome

NCT01174459 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 571

Last updated 2014-08-29

Study results available
· View outcomes & findings →

Summary

The survey is conducted to investigate the safety and efficacy of long-term use of BI-Sifrol Tablets in Restless Legs Syndrome (RLS) patients with or without renal dysfunction in routine medical practice.

Conditions

  • Restless Legs Syndrome

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-08-31
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01174459 on ClinicalTrials.gov